Interleukin 10 reduces mortality from severe peritonitis in mice | Zendy

Takeshi Kato | Zendy; A Murata | Zendy; Hiroshi Ishida | Zendy; H Toda | Zendy; Nobuo Tanaka | Zendy; Hirohito Hayashida | Zendy; Morito Monden | Zendy; Nariaki Matsuura∥ | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interleukin 10 reduces mortality from severe peritonitis in mice

Author(s) -

Takeshi Kato,

A Murata,

Hiroshi Ishida,

H Toda,

Nobuo Tanaka,

Hirohito Hayashida,

Morito Monden,

Nariaki Matsuura∥

Publication year - 1995

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.39.6.1336

Subject(s) - sepsis , tumor necrosis factor alpha , medicine , peritonitis , proinflammatory cytokine , cytokine , interleukin , immunology , pharmacology , inflammation

Interleukin 10 (IL-10) is known to suppress the induction of proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 and is itself induced by monocytes and macrophages during sepsis. We studied the therapeutic efficacy of IL-10 by testing its effect on the survival rate in the murine cecal ligation-and-puncture (CLP) model. Administration of 1 microgram or more of recombinant murine IL-10 6 h after induction of sepsis decreased lethality in septic mice significantly and also suppressed the elevation of circulating TNF after sepsis. However, treatment with the same dose of IL-10 simultaneously or 6 h before induction of CLP had no effect on survival, and treatment with anti-TNF antibody after induction of CLP had no effect on the survival rate. These data suggest that cytokine modulation with IL-10 is a potential candidate for the treatment of sepsis and sepsis-related multiple organ failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research